等待开盘 12-20 09:30:00 美东时间
-0.046
-5.08%
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
12-18 10:54
Morgan Stanley analyst Toni Kaplan maintains Advantage Solutions (NASDAQ:ADV) with a Equal-Weight and lowers the price target from $2 to $1.5.
12-17 21:46
Genpact demonstrates excellence in enabling agentic enterprise transformation within Salesforce ecosystem NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Genpact (NYSE: G), an agentic and advanced t...
11-13 21:05
Advantage Solutions (NASDAQ:ADV) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.03) by 340 percent. This is a 250 percent increase over losses of $(0.04) per share from
11-06 20:04
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
An announcement from Ardiden ( ($AU:ADV) ) is now available. Ardiden Limited ha...
10-29 05:43
Issues Letter to Shareholders Highlighting Significant Upside Potential If Proposed Sale to CoreWeave Is Not Approved Urges Shareholders to Vote AGAINST the Ill-Advised Transaction on the GO...
10-28 20:30
NEW COMPANY WILL BE A GLOBAL LEADER IN ADVANCED CATALYSTS AND ADDITIVES FOR THE REFINING AND PETROCHEMICAL INDUSTRIES NEW YORK, Oct. 27, 2025 /PRNewswire/ -- KPS Capital Partners, LP ("KPS")...
10-27 19:26
摩根士丹利发布研报称,香港交易所(00388)强劲的收入和利润增长将持续至2025年第三季度,这得益于2,860亿港元的强劲日均交易量(ADV)和高流通速度...
10-24 12:30
摩根士丹利发布研报称,香港交易所(00388.HK)强劲的收入和利润增长将持续至2025年第三季度,这得益于2,860亿港元的强劲日均交易量(ADV)和高流通速度驱动。伴随着更多证据显示金融体系周期触底,交易活动在香港资本市场活跃;维持港交所“增持”评级,目标价508港元。
10-24 10:50